Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

48.19 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 48.19
Bid (Size) 45.37 (1)
Ask (Size) 52.26 (1)
Prev. Close 48.19
Today's Range 48.19 - 48.19
52wk Range 25.49 - 58.47
Shares Outstanding 80,496,771
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of... 
From PR Newswire

Performance

YTD
-11.72%
-11.72%
1 Month
+12.23%
+12.23%
3 Month
+5.87%
+5.87%
6 Month
+30.35%
+30.35%
1 Year
+36.52%
+36.52%

More News

Read More
Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021
From GlobeNewswire News Releases
Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From GlobeNewswire News Releases
Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy
From GlobeNewswire News Releases
The NEJM publishes phase 3 PEGASUS study results comparing pegcetacoplan to eculizumab for PNH
From PR Newswire
Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
From GlobeNewswire News Releases
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
From GlobeNewswire News Releases
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Notable Thursday Option Activity: GILD, APLS, ESI
Tags Stocks
From Market News Video
ApellisPharmaceuticals Sees IBD RS Rating Improve To 77
From Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.